Trachoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
m (Changes made per Mahshid's request) |
m (Bot: Removing from Primary care) |
||
| Line 11: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
| Line 17: | Line 19: | ||
[[Category:Neglected diseases]] | [[Category:Neglected diseases]] | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
Latest revision as of 00:28, 30 July 2020
|
Trachoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Trachoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Trachoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Trachoma cost-effectiveness of therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.